# Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

> **NCT00634920** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 204 (actual)

## Conditions studied

- Renal Function

## Interventions

- **DRUG:** everolimus
- **DRUG:** cyclosporine A
- **DRUG:** Enteric Coated Mycophenolate Sodium (EC-MPS)
- **DRUG:** corticosteroids
- **DRUG:** Basiliximab

## Key facts

- **NCT ID:** NCT00634920
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2014-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634920, "Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00634920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*